LHON Gene Therapy Vector Prevents Visual Loss and Optic Neuropathy Induced by G11778A Mutant Mitochondrial DNA: Biodistribution and Toxicology Profile
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
PURPOSE: To demonstrate safety and efficacy of allotopic human ND4 for treatment of a Leber's hereditary optic neuropathy (LHON) mouse model harboring the G11778A mitochondrial mutation. METHODS: We induced LHON in mice by intravitreal injection of mutant (G11778A) human ND4 DNA, responsible for most cases of LHON, that was directed to mitochondria using an AAV2 vector to which we appended a mitochondrial targeting sequence to the VP2 capsid. We then attempted rescue of visual loss using our test article (ScAAV2-P1ND4v2) containing a synthetic nuclear encoded G11778G ND4 gene that was allotopically expressed. Control mice either were uninjected or received AAV2-GFP or AAV2-mCherry. We performed RT-PCR and confocal microscopy at 2 weeks post injection. Pattern electroretinograms (PERGs), spectral-domain optical coherence tomography (SD-OCT), histology, and transmission electron microscopy (TEM) were performed. For toxicology and biodistribution studies, the test article was administered intravitreally to rats and rhesus macaques at different doses. RESULTS: Mutant and wild-type ND4 were efficiently expressed in the mitochondria of retinal ganglion cells (RGCs). Visual function assessed by serial PERGs and retinal structure by serial SD-OCT showed a significant rescue by the test article. Histology and ultrastructural analysis confirmed that loss of RGCs and demise of axons was prevented by ScAAV2-P1ND4v2. Rat and nonhuman primate biodistribution studies showed that vector spread outside the injected eye into spleen and lymph nodes was minimal. Histopathology of tissues and organs including the eyes was comparable to that of uninfected and saline-injected eyes. CONCLUSIONS: Allotopically expressed wild-type ND4 prevents the phenotype induced by G11778A mitochondrial DNA with a toxicology profile acceptable for testing in a phase I clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies showed that rAAV2/2-ND4 efficiently rescued complex I dysfunction in cells carrying the m.11778G>A mutation and in an induced rat model of LHON.[12][13][14][15]”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, mutant versions of the ND4 and ND6 genes have been expressed using mitochondria-targeted AAV, to induce LHON phenotypes in mouse models [151,165,166,168].”
From The Mitochondrial Genome in Aging and Disease and the Future of Mitochondrial Therapeutics (2022) · cites this paper as [165]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This strategy has been successfully applied in cell models and safely translated in induced rodent LHON models with preservation of RGCs and visual function.9–12”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Despite these difficulties, some animal studies targeting the ATP6 and ND4 genes using AE have shown promising data [128,165,166,167].”
From The Mitochondrial Genome in Aging and Disease and the Future of Mitochondrial Therapeutics (2022) · cites this paper as [165]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN IMPORT INTO MITOCHONDRIA
Neupert, W. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.863 · Cited by 1,057
[Protein import into mitochondria].
Zaĭtseva, L. G., Tv, O., & Гринкевич, В. А. (2000) · PubMed · Cited by 972
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
IMPORT OF PROTEINS INTO MITOCHONDRIA
Glick, B., & Schatz, G. (1991) · Annual Review of Genetics · doi:10.1146/annurev.ge.25.120191.000321 · Cited by 578
Mitochondrial gene replacement in primate offspring and embryonic stem cells
Tachibana, M., Sparman, M., Sritanaudomchai, H., Ma, H., Clepper, L., Woodward, J., Li, Y., Ramsey, C., Kolotushkina, O., & Mitalipov, S. (2009) · Nature · doi:10.1038/nature08368 · Cited by 573
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Treatment for mitochondrial disorders
Pfeffer, G., Majamaa, K., Turnbull, D. M., Thorburn, D., & Chinnery, P. F. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004426.pub3 · Cited by 492
Riordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
Research works printed but not linked: 2
- Leber T. Uber hereditare und congenital-angelegete Sehner- verleiden. Graefes Archiv für klinsche und experimentelle Ophthalmologie. 1871;7:249-291.
- Harding AE, Sweeney MG, Govan GG, et al. Pedigree analysis in Leber hereditary optic neuropathy families with a patho- genic mtDNA mutation. Am J Hum Genet. 1995;57:77-86.
Cited by
Mitochondrial diseases: from molecular mechanisms to therapeutic advances
Wen, H., Deng, H., Li, B., Chen, J., Zhu, J., Zhang, X., Yoshida, S., & Zhou, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02044-3 · Cited by 222
Yu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7423 · Cited by 232
Gene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Self-citationGene Therapy for Leber Hereditary Optic Neuropathy
Guy, J., Feuer, W. J., Davis, J. L., Porciatti, V., Gonzalez, P. J., Koilkonda, R. D., Yuan, H., Hauswirth, W. W., & Lam, B. L. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.016 · Cited by 204
Self-citationMitochondrial function in development and disease
Rossmann, M. P., Dubois, S. M., Agarwal, S., & Zon, L. I. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048912 · Cited by 184
Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21587 · Cited by 182
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
Safety of rAAV2/2-ND4 gene therapy for leber hereditary optic neuropathy
Vignal, C., Uretsky, S., Fitoussi, S., Galy, A., Blouin, L., Girmens, J.-F., Bidot, S., Thomasson, N., Bouquet, C., Valero, S., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.12.036 · Cited by 99
Therapeutic Options in Hereditary Optic Neuropathies
Amore, G., Romagnoli, M., Carbonelli, M., Barboni, P., Carelli, V., & Morgia, C. L. (2020) · Drugs · doi:10.1007/s40265-020-01428-3 · Cited by 97
Drug Development for the Therapy of Mitochondrial Diseases
Weissig, V. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.09.002 · Cited by 97
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
Cwerman-Thibault, H., Augustin, S., Lechauve, C., Ayache, J., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.3 · Cited by 86
Leber Hereditary Optic Neuropathy: Review of Treatment and Management
Hage, R., & Vignal‐Clermont, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.651639 · Cited by 84
Engineered mitochondria in diseases: mechanisms, strategies, and applications
Li, M., Wu, L., Si, H., Wu, Y., Liu, Y., Zeng, Y., & Shen, B. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02081-y · Cited by 79
Gene Therapy for Mitochondrial Diseases: Current Status and Future Perspective
Donfrancesco, A. D., Massaro, G., Meo, I. D., Tiranti, V., Bottani, E., & Brunetti, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061287 · Cited by 65
Hohman, T. C. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_91 · Cited by 56
Wu, Y.-R., Wang, A.-G., Chen, Y., Yarmishyn, A. A., Buddhakosai, W., Yang, T., Hwang, D., Yang, Y.-P., Shen, C., Lee, H., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.020 · Cited by 53
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges
Falabella, M., Minczuk, M. A., Hanna, M. G., Viscomi, C. F., & Pitceathly, R. D. S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00715-9 · Cited by 47
Targeting mitochondrial function to treat optic neuropathy
Gueven, N., Nadikudi, M., Daniel, A., & Chhetri, J. (2016) · Mitochondrion · doi:10.1016/j.mito.2016.07.013 · Cited by 41
Wang, Y., Hu, L., Cui, P., Qi, L., Xing, L., & Jiang, H. (2021) · Advanced Materials · doi:10.1002/adma.202103307 · Cited by 39
Correction of Monogenic and Common Retinal Disorders with Gene Therapy
Sengillo, J. D., Justus, S., Cabral, T., & Tsang, S. H. (2017) · Genes · doi:10.3390/genes8020053 · Cited by 41
Marangoni, D., Bush, R. A., Zeng, Y., Wei, L. L., Ziccardi, L., Vijayasarathy, C., Bartoe, J. T., Palyada, K., Santos, M., Hiriyanna, S., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.11 · Cited by 38
Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates
Calkins, D. J., Yu-Wai-Man, P., Newman, N. J., Taiel, M., Singh, P., Chalmey, C., Rogue, A., Carelli, V., Ancian, P., & Sahel, J. A. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.013 · Cited by 37
Is there treatment for Leber hereditary optic neuropathy?
Peragallo, J. H., & Newman, N. J. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000212 · Cited by 37
Da Costa, R., Röger, C., Segelken, J., Barben, M., Grimm, C., & Neidhardt, J. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.16-19701 · Cited by 32
Current Advances in Gene Therapies of Genetic Auditory Neuropathy Spectrum Disorder
Saidia, A. R., Ruel, J., Bahloul, A., Chaix, B., Venail, F., & Wang, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030738 · Cited by 33
Gene Therapies for the Treatment of Leber Hereditary Optic Neuropathy
Sahel, J., Newman, N. J., Yu‐Wai‐Man, P., Vignal‐Clermont, C., Carelli, V., Biousse, V., Moster, M. L., Sergott, R. C., Klopstock, T., Sadun, A. A., et al. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000364 · Cited by 30
Stable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA Complex V null mutant
Boominathan, A., Vanhoozer, S., Basisty, N., Powers, K., Crampton, A. L., Wang, X., Friedricks, N., Schilling, B., Brand, M. D., & O'Connor, M. S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw756 · Cited by 27
Clinical Approaches for Mitochondrial Diseases
Hong, S., Kim, S., Kim, K., & Lee, H. (2023) · Cells · doi:10.3390/cells12202494 · Cited by 28
Mitochondrial dysfunction: Related diseases, influencing factors, and detection
Li, Z., Li, S., Chen, W., Zhang, Z., Pan, C., Peng, L., Cheng, C., Zhu, J., Sun, H., & Dai, Z. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20250005 · Cited by 25
Talla, V., Koilkonda, R. D., & Guy, J. R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01857-6 · Cited by 22
Self-citationLeber’s Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development
Karaarslan, C. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01113-2 · Cited by 21
Gao, Y., Guo, L., Wang, F., Wang, Y., Li, P., & Zhang, D. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.10.004 · Cited by 20
Liu, Y., Eastwood, J. D., Alba, D. E., Velmurugan, S., Sun, N., Porciatti, V., Lee, R. K., Hauswirth, W. W., Guy, J., & Yu, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00333-6 · Cited by 19
Self-citationNeuroimaging in Leber Hereditary Optic Neuropathy: State-of-the-art and future prospects
Chow-Wing-Bom, H. T., Callaghan, M. F., Wang, J., Wei, S., Dick, F., Yu‐Wai‐Man, P., & Dekker, T. M. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103240 · Cited by 18
Leber Hereditary Optic Neuropathy: Bringing the Lab to the Clinic
Rasool, N., Lessell, S., & Cestari, D. M. (2016) · Seminars in Ophthalmology · doi:10.3109/08820538.2015.1115251 · Cited by 15
The Mitochondrial Genome in Aging and Disease and the Future of Mitochondrial Therapeutics
Saravanan, S., Lewis, C. J., Dixit, B., O’Connor, M. S., Stolzing, A., & Boominathan, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020490 · Cited by 13
Mitochondrial Transfer of the Mutant Human ND6T14484C Gene Causes Visual Loss and Optic Neuropathy
Yu, H., Sant, D. W., Wang, G., & Guy, J. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.11.1 · Cited by 13
Self-citationWassmer, S., Repentigny, Y. D., Sheppard, D., Lagali, P. S., Fang, L., Coupland, S. G., Kothary, R., Guy, J. R., Hauswirth, W. W., & Tsilfidis, C. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.8.49 · Cited by 12
Self-citationFrom Bench to Bedside—Delivering Gene Therapy for Leber Hereditary Optic Neuropathy
Chen, B. S., & Yu‐Wai‐Man, P. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041282 · Cited by 14
Gene therapy for Leber hereditary optic neuropathy
Battista, M., Carelli, V., Bottazzi, L., Bandello, F. M., Cascavilla, M. L., & Barboni, P. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2359015 · Cited by 10
Schultz, A., Cheng, S.-Y., Kirchner, E. G., Costello, S. M., Miettinen, H. M., Chaverra, M. E., King, C., George, L., Zhao, X., Narasimhan, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45376-w · Cited by 9
Mitochondrial Genetics and Optic Neuropathy
Wiggs, J. L. (2015) · Annual Review of Vision Science · doi:10.1146/annurev-vision-082114-035651 · Cited by 8
Current Concepts and Emerging Gene Therapies for Inherited Retinal Diseases
Gregori, N. Z., Hussain, R. M., Kay, C. N., Lam, B. L., Dermer, H., & Davis, J. L. (2018) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000259 · Cited by 7
Kurimoto, T., Ueda, K., Mori, S., Sakamoto, M., Yamada‐Nakanishi, Y., Matsumiya, W., & Nakamura, M. (2019) · Clinical ophthalmology · doi:10.2147/opth.s204669 · Cited by 7
Siedlecki, J., Koenig, S. F., Catarino, C. B., Schaumberger, M. M., Schworm, B., Priglinger, S. G., Rudolph, G., von Livonius, B., Klopstock, T., & Priglinger, C. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-320580 · Cited by 7
Wilson, K., Holjencin, C. E., Lee, H., Annamalai, B., Ishii, M., Gilbert, J. L., Jakymiw, A., & Rohrer, B. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102449 · Cited by 8
Newman, N. J., Schniederjan, M., Mendoza, P. R., Calkins, D. J., Yu‐Wai‐Man, P., Biousse, V., Carelli, V., Taiel, M., Rugiero, F., Singh, P., et al. (2022) · BMC Neurology · doi:10.1186/s12883-022-02787-y · Cited by 6
Lyu, L., Beibei, Q. I. E., He, Y., Chen, F., & Liu, B. C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07420-3 · Cited by 5
Technological advances in the diagnosis and management of inherited optic neuropathies
Britton, J. O. T., Yu‐Wai‐Man, P., & Chen, B. S. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1609033 · Cited by 4
Bernstein, S. L., Guo, Y., Mehrabian, Z., & Miller, N. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415604 · Cited by 4
Velmurugan, S., Chou, T., Eastwood, J. D., Porciatti, V., Liu, Y., Hauswirth, W. W., Guy, J. R., & Yu, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1119724 · Cited by 4
Self-citationAdvances in research on Leber's hereditary optic neuropathy
Zhou, Q., Liu, Z., Sun, J., Lü, L., Han, E., & Zhang, L. (2024) · Ocular genetics and omics. · doi:10.1016/j.ogo.2024.100002 · Cited by 3
Traitements médicaux dans la neuropathie optique héréditaire de Leber
Hage, R. (2022) · Journal Français d Ophtalmologie · doi:10.1016/s0181-5512(22)00447-8 · Cited by 3
Chekuri, A., Kondabolu, K., Kirchner, E. G., Koli, S., Chagnon, M., Krasniqi, D., Stern, M. E., Bolduc, J., Romano, G., Pagani, F., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102788 · Cited by 3
Bénit, P., Schiff, M., Cwerman‐Thibault, H., Corral‐Debrinski, M., & Rustin, P. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1117972 · Cited by 4
Kovač, L., Volk, M., Habjan, M. Š., & Hawlina, M. (2023) · Stresses · doi:10.3390/stresses3010028 · Cited by 2
Gene therapy and mRNA drugs approach for mitochondrial OXPHOS deficiencies
Garone, C., Sabeni, S., & Carli, S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.036 · Cited by 1
ELP1 gene augmentation restores visual function in a mouse model of familial dysautonomia
Cheng, H., Koli, S., Lewis, K. J., Ketchale, S., Anvarinia, Y., Erdoes, M. P., Liu, Y., Keiper, C. E., Estelien, R., Chagnon, M., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.046 · Cited by 1
Induced pluripotent stem cell–based leber hereditary optic neuropathy model
Wu, Y., Yang, T., Yarmishyn, A. A., Chen, S., Wang, A.-G., & Chiou, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85764-2.00013-2
Peragallo, J. H., Biousse, V., & Newman, N. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6616-0.00054-2
Nicotinamide Riboside Attenuated Cell Damage Induced by the MT-ND4 (G11778A) MutationPreprint
Fang, L., Yang, M., Fu, K., Qu, D., Hu, J., & Huang, T. (2025) · Research Square · doi:10.21203/rs.3.rs-8295635/v1
Oxidative stress imbalance and cellular damage mediated by the ND4 G11778A mutation
Fang, L., Fu, K., Yang, M., Xu, Y., Ukamaka, E. S., Qu, D., Huang, T., & Hu, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-40061-0
Gene therapy clinical trials for inherited eye diseases: The pediatric perspective
Sandali, A., Nikolaidou, A., Gianni, T., Tsoukala, Z., Tsinopoulos, I., & Lamprogiannis, L. P. (2026) · European Journal of Ophthalmology · doi:10.1177/11206721261478166
Metadata
- Authors
- Koilkonda, R., Yu, H., Talla, V., Porciatti, V., Feuer, W. J., Hauswirth, W. W., Chiodo, V., Erger, K. E., Boye, S. L., Lewin, A. S., Conlon, T. J., Renner, L., Neuringer, M., Detrisac, C., & Guy, J.
- Affiliations
- University of Miami (US)
- University of Florida (US)
- Oregon National Primate Research Center (US)
- Corresponding author
- Guy, J.
- ORCID
- Venue
- Investigative Ophthalmology & Visual Science
- Published
- 2014-10-23
- Volume
- 55
- Issue
- 12
- Pages
- 7739-7753
- ISSN
- 0146-0404 (ISSN-L)
- PMC
- PMC4249950
- OpenAlex
- W2313131721
- Cited by
- 65
- References
- 38
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 2 · 2023: 6 · 2022: 11 · 2021: 7 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 7 · 2015: 5
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Research to Prevent Blindness (R24EY018600, P30 EY014801)
- University of Florida
- National Institutes of Health (P51OD011092)
- Oregon National Primate Research Center (P51OD011092)
- National Eye Institute (R01EY123555, P30EY021721, R01EY01714, R24EY018600, R01EY019077, P30EY014801)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- Leber's hereditary optic neuropathy, AAV2 vector, mitochondrial targeting sequence, retinal ganglion cells, vector biodistribution, intravitreal injection, mouse model, rhesus monkeys, rats
- MeSH terms
- Animals, Axons, Blindness, Disease Models, Animal, DNA, Mitochondrial, Electroretinography, Genetic Vectors, Macaca mulatta, Mitochondria, NADH Dehydrogenase, Retinal Ganglion Cells, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence, Microscopy, Electron, Transmission, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.